New technologies based around functional polymers and ion exchange materials promise to shorten time to market, optimise drug formulation, and reduce costs
Rohm and Haas has launched its Advanced Release Technologies (Art), a major new line of patented technologies for drug development.
Art will enable pharmaceutical companies to bring products to market faster and make significant cost savings in formulation and the design of drug delivery mechanisms.
Early access customers among the world's leading pharmaceutical manufacturers are reportedly excited by the concept of Advanced Release Technologies and are already working with the Art teams at Rohm and Haas to improve their processes.
Art is a range of patented technologies incorporating some of the company's most widely used excipients bundled with supporting expertise to help customers to optimise their formulation processes.
Art is based around functional polymers and ion exchange materials and comprise a range of technologies designed to optimise key stages of the drug development process including dissolution testing and formulations performance.
Key applications of Art will include their use as active ingredients and excipients, in taste-masking, tablet disintegration, sustained release and drug stabilisation. Drug development has depended for decades on critical products from Rohm and Haas, including Amberlite and Duolite, two of the company's best-known brand names, but customers have needed to develop essential processes themselves, at huge cost in time and expertise.
Now, Advanced Release Technologies will support pharmaceutical companies through all stages of formulation, from process design through feasibility studies and even to medium-scale production, as customers require, using benchmark pharmaceutically accepted excipients from Rohm and Haas upon which the industry has come to depend.
Established among generations of pharmaceutical technologists as their supplier of choice for critical products, with the introduction of ART Rohm and Haas moves up from being a manufacture of their key chemicals to become their expert partner throughout the whole process of drug development and the design of their drug delivery technologies.
